RecruitingNCT07128966
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Joined Bio
- Principal Investigator
- Chris Ianelli, MD, MDJoined Bio
- Intervention
- Observation(other)
- Enrollment
- 100000 enrolled
- Eligibility
- 18-90 years · All sexes
- Timeline
- 2025 – 2036
Study locations (1)
- Joined Bio, Lexington, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07128966 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT05538208The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT05835310An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsAstraZeneca
- RECRUITINGNANCT06586710Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLEMeyer Children's Hospital IRCCS
- RECRUITINGPHASE2NCT05039619A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsHoffmann-La Roche
- ACTIVE NOT RECRUITINGPHASE2NCT04179032Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)GlaxoSmithKline